We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nexeon MedSystems Begins Trading and NXNN
News

Nexeon MedSystems Begins Trading and NXNN

Nexeon MedSystems Begins Trading and NXNN
News

Nexeon MedSystems Begins Trading and NXNN

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nexeon MedSystems Begins Trading and NXNN"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Company is finalizing development of its deep brain stimulation system for the treatment of symptoms associated with Parkinson's disease.

"I'm proud of our management team for implementing and delivering on innovative financing strategies in much the same fashion as our engineers do," said Nexeon CEO Will Rosellini. "Our next step is to uplist to a major exchange, we hope to accomplish this as soon as possible."


In June 2017, the Securities and Exchange Committee (SEC) declared effective the Company's S-1 Registration Statement. The S-1 registered 5,332,496 shares of the Company's common stock. Nexeon has previously reported it has just over 26M issued and outstanding shares.

Trading has commenced after recent announcements that include acquisition of profitable Belgian manufacturer, published analyst research pointing to $2.40 target price, and awarded research funds from the National Institutes of Health.

The Company is finalizing development of its deep brain stimulation system for the treatment of symptoms associated with Parkinson's disease. A former generation of the technology received a CE Mark, but Nexeon has since improved and added features to the system based on inputs from key opinion leaders in preparation for a commercial launch in Europe in 2018.

Advertisement